TOP2A and lung carcinoma: In addition, DEX reduced in vitro TOP2A levels and the accumulation of DOX-induced DSB in fibrosarcoma-derived cells but not in lung cancer cells, thereby highlighting the inconsistency of DEX in interfering with the anticancer effects of DOX as was also observed in the current study.